News
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
Zacks Investment Research on MSN21h
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...
European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...
The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.
The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...
Stocktwits on MSN5d
Argenx Gets European Commission Approval For Drug To Treat Rare Autoimmune Disease, But Stock Fails To Garner Retail AttentionNasdaq-listed shares of argenx SE (ARGX) rose 2% by Friday afternoon after the company announced that the European Commission ...
This regulatory approval is the second for VYVGART SC in Europe, which first received approval as an add-on to standard therpy for the treatment of adult patients with generalized myasthenia gravis ...
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...
A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback